France's drug industry association (LEEM) has responded to an annual report by the French agency for health product safety (Afssaps) on pharmaceutical advertising. In 2006, 24 requests for direct to consumer advertising were rejected by the agency and 13 communications to health care professionals were prohibited, out of 9,620 applications.
Commenting on the figures, the LEEM said: "the Afssaps publication concerning its advertising control activities show how respectful the firms are of the regulations, since a very small number of advertisements aimed at health care professionals are forbidden (0.25%), as well as a very small number of requests for general public viewing are refused (2%)."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
LEEM comment on France's pharma marketing rules
France's drug industry association (LEEM) has responded to an annual report by the French agency for health product safety (Afssaps) on pharmaceutical advertising. In 2006, 24 requests for direct to consumer advertising were rejected by the agency and 13 communications to health care professionals were prohibited, out of 9,620 applications.
Commenting on the figures, the LEEM said: "the Afssaps publication concerning its advertising control activities show how respectful the firms are of the regulations, since a very small number of advertisements aimed at health care professionals are forbidden (0.25%), as well as a very small number of requests for general public viewing are refused (2%)."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
Become a subscriber
£820
Or £77 per month
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze